ReveraGen's first press release announcing our partnership with NIH's TRND program can be viewed on our website. Check it out.

Washington Business Journal covers the new additions to our team here at ReveraGen BioPharma. bit.ly/omzr9t

Our new website is up! Check us out at www.reveragen.com!

We are pleased to announce that ReveraGen was one of 3 first round selected companies for the NIH's TRND to further develop our drug for DMD

Validus Biopharma is now ReveraGen. Follow us here for updates as we continue our small molecule development for muscular dystrophy.